Feb 24, 2026 07:05AM
Jan 12, 2026 07:00AM
Dec 3, 2025 05:05PM
Dec 3, 2025 05:05PM
Oct 30, 2025 07:05AM
Oct 20, 2025 07:00AM
Jul 31, 2025 07:05AM Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Jul 29, 2025 07:07AM
Jul 28, 2025 07:19PM
May 7, 2025 07:00AM
Feb 28, 2025 07:05AM
Jan 13, 2025 09:07AM
Jan 13, 2025 09:00AM
Nov 5, 2024 07:05AM Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Aug 1, 2024 07:05AM
May 7, 2024 07:05AM
Feb 27, 2024 07:05AM
Jan 8, 2024 09:03AM
Jan 8, 2024 09:00AM
Dec 11, 2023 07:04AM
Dec 11, 2023 07:00AM EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
Nov 1, 2023 07:05AM
Oct 2, 2023 07:00AM
Jul 31, 2023 07:00AM
May 4, 2023 04:05PM
Feb 21, 2023 04:13PM
Feb 21, 2023 04:13PM
Nov 18, 2022 12:25PM Apellis Pharmaceuticals (APLS) Still Has No FDA AdCom, Which is a Positive - Cowen
Nov 18, 2022 07:01AM
Nov 18, 2022 07:00AM
Nov 18, 2022 07:00AM
Nov 7, 2022 04:05PM
Nov 7, 2022 04:05PM
Nov 3, 2022 09:05AM
Nov 3, 2022 09:05AM Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
Aug 9, 2022 04:01AM
Aug 9, 2022 04:00AM
Aug 8, 2022 04:05PM
Aug 8, 2022 04:05PM
Jul 19, 2022 07:04AM
Jul 19, 2022 07:00AM
Jul 19, 2022 07:00AM Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)
Jun 10, 2022 05:34AM
Jun 10, 2022 03:00AM
Jun 10, 2022 03:00AM
May 12, 2022 11:05AM
May 12, 2022 11:05AM
May 5, 2022 06:49AM
May 4, 2022 04:05PM Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
May 4, 2022 04:05PM

15,404 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All